Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)
Lung Cancer Update
00:00
PDL1 High - Is There a Benefit?
Tesalizumab based on Empower 010 was approved for resected lung cancer. We know immunotherapy can improve disease-free survival. In PDL1 positive, resected stage two-three, there was a DFS benefit. The greatest benefit was in PDL1 high. This really fit with our preconceived notions of how immunotherapy should work. But the Pembrolyzumab data are strong enough that I do recommend it.
Transcript
Play full episode
